MDS 2023 | Distinguishing and choosing between intensive and non-intensive therapies for patients with HR-MDS
Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, discusses the distinction between intensive and non-intensive treatment regimens for patients with high-risk myelodysplastic syndromes (HR-MDS), explaining which patient subsets may benefit from these therapies. Prof. Platzbecker explains that the classification of intensive versus non-intensive therapy is still largely based on tradition, and that some novel combination therapies have side effects that are typically associated with intensive approaches. Prof. Platzbecker further notes treatment regimens of varying intensity which are available for older and younger patients with HR-MDS. This interview took place at the 17th International Congress on Myelodysplastic Syndromes (MDS) 2023, held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
